<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03264482</url>
  </required_header>
  <id_info>
    <org_study_id>THUVAP VS M-TURP</org_study_id>
    <nct_id>NCT03264482</nct_id>
  </id_info>
  <brief_title>High Power Thulium Vaporization vs Transurethral Resection of the Prostate for Treatment of BPH</brief_title>
  <official_title>Treatment of Benign Prostatic Hyperplasia: High Power Thulium Laser Front Fire Vaporization VS Transurethral Resection - A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      the investigators plan to test Thulium laser vaporization using high power ( 200w ) Front&#xD;
      fire vaporization compared to standard M-TURP in reduction of LUTS secondary to BPH in a&#xD;
      prospective randomized trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      When Lower Urinary Tract Symptoms (LUTS) are refractory to medical therapy and bothersome&#xD;
      enough to warrant surgical intervention, transurethral resection of the prostate (TURP) has&#xD;
      been the historical reference-standard procedures for prostate size between 30-80 ml for&#xD;
      years.&#xD;
&#xD;
      Over the past decade, New minimally invasive surgical therapies (MIST), new medications, and&#xD;
      novel combinations of medical therapies have expanded the number of treatment options ranging&#xD;
      from watchful waiting to open surgery. The range of treatment options is as broad as the BPH&#xD;
      spectrum of symptoms.&#xD;
&#xD;
      These treatment options include prostate vaporization, resection and enucleation using&#xD;
      various energy sources , however the main theme for all these new procedures that they were&#xD;
      done using physiological saline as an irrigant nullifying the risk of TUR syndrome.&#xD;
&#xD;
      One of the biggest changes in surgical treatment of BPH over the past 2 decades has been the&#xD;
      introduction and use of lasers. Two-micron (Thulium) continuous-wave (CW) laser may have&#xD;
      several advantages, including sufficient homeostasis with minimal thermal injury, more&#xD;
      precise tissue incision, and operation in CW/pulsed modes. Pieces of the prostate are&#xD;
      vaporized small enough to evacuate through the resectoscope sheath and use of a mechanical&#xD;
      tissue morcellator is not required.&#xD;
&#xD;
      The introduction of the latest generation of the Thulium laser namely &quot;200w laser &quot; raises&#xD;
      the expectations of the prostate vaporization.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 20, 2017</start_date>
  <completion_date type="Actual">December 1, 2020</completion_date>
  <primary_completion_date type="Actual">December 2, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>IPSS score at 12 months .</measure>
    <time_frame>12 months</time_frame>
    <description>international prostate symptom score (both voiding &amp; storage symptom subscores )</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Benign Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>THUVAP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>thulium vaporization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>M-TURP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>monopolar transurethral resection</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>M-TURP</intervention_name>
    <description>endoscopic resection of the prostatic adenoma</description>
    <arm_group_label>M-TURP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>THUVAP</intervention_name>
    <description>vaporization of prostatic adenoma via THULIUM laser</description>
    <arm_group_label>THUVAP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients' age ≥50 years&#xD;
&#xD;
          -  LUTS secondary to BOO due to BPH who failed medical treatment&#xD;
&#xD;
          -  International prostate symptom scores (IPSS) &gt;15 and bother score (QOL) ≥ 3 (according&#xD;
             to IPSS question 8)&#xD;
&#xD;
          -  Peak urinary flow rate (Qmax) &lt;15 ml/sec with at least 125 ml voided volume or&#xD;
             Patients with acute urine retention secondary to BPH who failed trial of voiding on&#xD;
             medical treatment.&#xD;
&#xD;
          -  ASA (American society of anaesthesiologists) score ≤3.&#xD;
&#xD;
          -  TRUS prostate size between 30-80 ml&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with neurological disorder which might affect bladder function as&#xD;
             cerebrovascular stroke, Parkinson disease&#xD;
&#xD;
          -  Active urinary tract infection,&#xD;
&#xD;
          -  Presence of active bladder pathology (within the last 2 years)&#xD;
&#xD;
          -  Known prostate cancer patients will be excluded preoperatively on the basis of digital&#xD;
             rectal examination, prostate specific antigen level, and TRUS imaging followed by&#xD;
             prostate biopsies if necessary.&#xD;
&#xD;
          -  Patient has a disorder of the coagulation cascade (e.g., liver cell failure) or&#xD;
             disorders that affect platelet count or function (e.g., von Willebrand disease) that&#xD;
             would put the subject at risk for intraoperative or postoperative bleeding.&#xD;
&#xD;
          -  Patient is unable to discontinue anticoagulant and antiplatelet therapy preoperatively&#xD;
             (3-5 d) except for low-dose aspirin (e.g., 100 mg).&#xD;
&#xD;
          -  Patient has had an acute myocardial infarction or open-heart surgery &lt;180 days prior&#xD;
             to the date of informed consent&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed M. Elshal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mansoura University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Urology and nephrology center</name>
      <address>
        <city>Al Manşūrah</city>
        <state>DK</state>
        <zip>35516</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 14, 2017</study_first_submitted>
  <study_first_submitted_qc>August 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 29, 2017</study_first_posted>
  <last_update_submitted>July 24, 2021</last_update_submitted>
  <last_update_submitted_qc>July 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mansoura University</investigator_affiliation>
    <investigator_full_name>Ahmed Elshal</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

